BioMarin Pharmaceutical Inc.
BMRN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2,853,915 | $2,419,226 | $2,096,039 | $1,846,275 |
| % Growth | 18% | 15.4% | 13.5% | – |
| Cost of Goods Sold | $580,235 | $532,062 | $503,023 | $470,515 |
| Gross Profit | $2,273,680 | $1,887,164 | $1,593,016 | $1,375,760 |
| % Margin | 79.7% | 78% | 76% | 74.5% |
| R&D Expenses | $747,184 | $746,773 | $649,606 | $628,793 |
| G&A Expenses | $532,300 | $404,000 | $372,900 | $354,300 |
| SG&A Expenses | $1,009,000 | $892,400 | $823,200 | $759,400 |
| Sales & Mktg Exp. | $476,700 | $488,400 | $450,300 | $405,100 |
| Other Operating Expenses | $33,282 | $62,217 | -$40,764 | $69,908 |
| Operating Expenses | $1,789,466 | $1,701,390 | $1,432,042 | $1,458,101 |
| Operating Income | $484,214 | $185,774 | $160,974 | -$82,341 |
| % Margin | 17% | 7.7% | 7.7% | -4.5% |
| Other Income/Exp. Net | $57,549 | $2,789 | -$11,398 | $6,991 |
| Pre-Tax Income | $541,763 | $188,563 | $149,576 | -$75,350 |
| Tax Expense | $114,904 | $20,918 | $8,015 | -$11,270 |
| Net Income | $426,859 | $167,645 | $141,561 | -$64,080 |
| % Margin | 15% | 6.9% | 6.8% | -3.5% |
| EPS | 2.25 | 0.89 | 0.76 | -0.35 |
| % Growth | 152.8% | 17.1% | 317.1% | – |
| EPS Diluted | 2.21 | 0.88 | 0.75 | -0.35 |
| Weighted Avg Shares Out | 190,027 | 187,834 | 185,266 | 182,852 |
| Weighted Avg Shares Out Dil | 196,708 | 191,595 | 188,963 | 182,852 |
| Supplemental Information | – | – | – | – |
| Interest Income | $74,883 | $58,339 | $18,034 | $10,482 |
| Interest Expense | $12,666 | $17,335 | $15,970 | $15,337 |
| Depreciation & Amortization | $96,426 | $104,386 | $101,969 | $108,039 |
| EBITDA | $650,528 | $306,773 | $265,359 | $47,433 |
| % Margin | 22.8% | 12.7% | 12.7% | 2.6% |